Myriad Genetics, Inc. MYGN is well-poised to grow in the coming quarters due to its impressive cadence of product launches. The company is also progressing well in its refreshed long-term strategy to ...

Myriad Genetics, Inc.’s MYGN Oncology growth strategy, which focuses on expanding companion diagnostics and market growth through new clinical guidelines, is poised to drive growth in the upcoming ...

In the preceding three months, 4 analysts have released ratings for Myriad Genetics (NASDAQ:MYGN), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments ...

The company posted an unexpected profit in its latest reported quarter. That was accompanied by a double-digit improvement in revenue. That morning, before market open, Fulgent unveiled its ...

Fulgent Genetics is a technology-driven company focused on clinical diagnostics and therapeutics, with recent expansion into precision medicine. FLGT's stock presents mixed signals with potential ...

Myriad Genetics, Inc. MYGN focuses on the expansion of companion diagnostics, market expansion through new clinical guidelines and providing new offerings in its Oncology business. The company plans ...